Pure Global AI
NCT06094985Recruiting

Prognostic Markers for a Better Follow-up in Head and Neck Cancer.

Karolinska InstitutetClinicalTrials.govgenetic
Verified
Study focus
Disease/Condition
Head and Neck Cancer
Drug/Device/Intervention
DNA exome sequencing of tumor and blood
Study type
Observational
Intervention type
genetic
Sponsor & location
Primary sponsor
Karolinska Institutet
Location
Stockholm, Sweden
Timeline & enrollment
Phase
N/A
Start date
Nov 01, 2023
End date
May 31, 2026
Enrollment
20 participants
Primary outcome

Recurrence,Survival,Treatment response

Summary

To identify tumor specific DNA mutations and aberrations and to follow these in blood over
 time to predict treatment response/survival and secondly to correlate presence of these
 markers in blood to pathological parameters (LVI, Pn, WPOI and margins), radiological
 findings and to tumor stage.

ICD-10 classifications
Malignant neoplasm of other and ill-defined sites: Head, face and neckMalignant neoplasm: Skin of scalp and neckMalignant neoplasm: Connective and soft tissue of head, face and neckCarcinoma in situ: Skin of scalp and neckSecondary and unspecified malignant neoplasm: Lymph nodes of head, face and neck
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06094985
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06094985 through Pure Global AI's free database. This phase not specified trial is sponsored by Karolinska Institutet and is currently Recruiting. The study focuses on Head and Neck Cancer. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.